Vor BiopharmaVOR -3.09%32 Current Ratio is 31.15 as of Mar. 2026, which is 197% above its 10-year median of 10.49. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Vor Biopharma ranks better than 96.81% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vor Biopharma's current ratio for the quarter that ended in Mar. 2026 was 31.15.
Vor Biopharma has a current ratio of 31.15. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Vor Biopharma's Current Ratio or its related term are showing as below:
VOR'
s Current Ratio Range Over the Past 10 Years
Min: 0.12 Med: 10.49 Max: 31.15
Current: 31.15
During the past 8 years, Vor Biopharma's highest Current Ratio was 31.15. The lowest was 0.12. And the median was 10.49.
VOR's Current Ratio is ranked better than 96.81% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs VOR: 31.15
Vor Biopharma (NAS:VOR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vor Biopharma Current Ratio Related Terms
Vor Biopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Vor Biopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vor Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vor Biopharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vor Biopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vor Biopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vor Biopharma (VOR) has a Current Ratio of 31.15 as of Mar. 2026. This is 197% above median its historical median of 10.49. Over the past decade, Vor Biopharma's Current Ratio has ranged from 0.12 to 31.15. According to the industry distribution chart, Vor Biopharma ranks #45 out of 1410 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Vor Biopharma's Current Ratio too high?
Vor Biopharma's current Current Ratio of 31.15 is 197% above median its 10-year median of 10.49. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 31.15. The Biotechnology industry median Current Ratio is 3.89. Vor Biopharma's value of 31.15 is 700.8% above this industry median. Based on the distribution chart, Vor Biopharma ranks #45 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's Current Ratio compare to ODTX and ANNX?
According to the Biotechnology industry distribution chart, Vor Biopharma ranks #45 out of 1410 companies for Current Ratio. This places Vor Biopharma in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Vor Biopharma's value of 31.15 is 700.8% above this benchmark. Historically, Vor Biopharma's own Current Ratio has ranged from 0.12 to 31.15 over the past decade. While the company's 10-year median is 10.49 vs. the industry median of 3.89, Vor Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vor Biopharma's current Current Ratio of 31.15 is 700.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vor Biopharma's current Current Ratio is 31.15, which is 197% above median its own 10-year median of 10.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current Current Ratio of 31.15. The current Current Ratio is 31.15, which is 197% above median its 10-year median of 10.49 and 700.8% above the Biotechnology industry median of 3.89. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vor Biopharma (VOR), the current Current Ratio is 31.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score
Get the complete analysis for VOR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VOR has been successfully added to your 
